OpGen rises after sale of certain diagnostic platform tests

CapForce

12/10/2023 12:08

** Shares of diagnostic firm OpGen Inc  OPGN.O  rise over
eight-fold to $2.88 premarket  
    ** Co says its German unit Curetis has received an advance
payment of 750,000 euros ($796,575) related to the sale of some
products from its proprietary rapid molecular testing platform,
Unyvero A50 
    ** Says the final purchase of the products will be made
after reaching a mutual agreement with the "strategic partner"
    ** The strategic partner may purchase additional Unyvero A50
systems from Curetis - OPGN
    ** Co intends to use the advance payment to fund operations
of its units, Curetis and Ares Genetics, while it negotiates
with the strategic partner
    ** Unyvero A50 amplifies several different DNA sequences
simultaneously to detect disease causing agents - OPGN  
    ** As of last close, stock down 88% YTD

    ($1 = 0.9415 euros)

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))